According to the latest report by IMARC Group, titled “Xerostomia (Dry Mouth Disease) Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global xerostomia (dry mouth disease) therapeutics market share. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The global xerostomia (dry mouth disease) therapeutics market size reached US$ 714 Million in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 893 Million by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2023-2028.
Xerostomia, or dry mouth, represents symptoms or sensations of oral dryness that are generally caused, on account of a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, Alzheimer’s disorder, etc.
It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, mitigate bad breath and taste disorders, etc. As a result, xerostomia therapeutics are used across numerous hospitals and clinics to deal with decreased salivary gland function.
Request For Sample Report: https://www.imarcgroup.com/xerostomia-therapeutics-market/requestsample
The growing incidences of dry mouth, especially among the geriatric population, owing to medicine side-effects of radiotherapy and chemotherapy and the inflating need for dry mouth relief products, are among the key factors stimulating the xerostomia (dry mouth disease) therapeutics market.
Moreover, the increasing utilization of several prescription-based toothpastes, vitamin gummies, medicines, etc., for treating Sjogren’s syndrome, Alzheimer’s diseases, human immunodeficiency virus (HIV), etc., that cause xerostomia is acting as another significant growth-inducing factor.
Besides this, the rising consumer awareness towards the early diagnosis of xerostomia, continuous enhancements in healthcare expenditures, and the development of diverse diagnostic technologies are positively influencing the global market. Furthermore, the easy availability of numerous therapeutic drugs and extensive investments in R&D activities are expected to fuel the xerostomia (dry mouth disease) therapeutics market over the forecasted period.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).
The report has been segmented the market into following categories:
Breakup by Type:
- Artificial Saliva/Saliva Substitutes
- Salivary Stimulants
Breakup by Drug Type:
Breakup by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Breakup by End-Use Sector:
- Commercial and Industrial
Based on the end-use sector, the report finds that the utility sector dominates the market. There are many ongoing development projects undertaken by various nations, which require a continuous flow of electricity. Owing to this, there is a rising demand for power inverters in this sector.
Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=6439&flag=C
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 |
Africa and Europe :- +44-702-409-7331 |
Asia: +91-120-433-0800, +91-120-433-0800